{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:41:05Z","timestamp":1788734465917,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In 2017, a new treatment by nusinersen, an antisense oligonucleotide delivered by repeated intrathecal injections, became available for patients with spinal muscular atrophy (SMA), whereas clinical trials had mainly involved children. Since 2020, the oral, selective SMN2-splicing modifier risdiplam has been available with restrictions evolving with time. In this peculiar context of lack of data regarding adult patients, many questions were raised to define the indications of treatment and the appropriate follow-up in this population. To homogenize access to treatment in France, a national multidisciplinary team meeting dedicated to adult SMA patients, named SMA multidisciplinary team meeting, (SMDTs) was created in 2018. Our objective was to analyze the value of SMDTs in the decision-making process in SMA adult patients and to provide guidelines about treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From October 2020 to September 2021, data extracted from the SMDT reports were collected. The primary outcome was the percentage of cases in which recommendations on validating treatment plans were given. The secondary outcomes were type of treatment requested, description of expectations regarding treatment and description of recommendations or follow-up and discontinuation. Data were analyzed using descriptive statistics. Comparisons between the type of treatment requested were performed using Mann\u2013Whitney test or the Student t test for quantitative data and the Fisher\u2019s exact test or the \u03c7<jats:sup>2<\/jats:sup> test for qualitative data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cases of 107 patients were discussed at the SMDTs with a mean age of 35.3 (16\u201362). Forty-seven were SMA type 2, and 57 SMA type 3. Twelve cases were presented twice. Out of 122 presentations to the SMDTs, most of requests related to the initiation of a treatment (nusinersen (n\u2009=\u200946), risdiplam (n\u2009=\u200954), treatment without mentioning preferred choice (n\u2009=\u20095)) or a switch of treatment (n\u2009=\u200912). Risdiplam requests concerned significantly older patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), mostly SMA type 2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), with greater disease severity in terms of motor and respiratory function compared to requests for nusinersen. In the year prior to presentation to the SMDTs, most of the patients experienced worsening of motor weakness assessed by functional tests as MFM32 or other meaningful scales for the most severe patients. Only 12% of the patients discussed had a stable condition. Only 49\/122 patients (40.1%) expressed clear expectations regarding treatment. The treatment requested was approved by the SMDTs in 72 patients (67.2%). The most common reasons to decline treatment were lack of objective data on the disease course prior discussion to the SMDTs or inappropriate patient\u2019s expectations. Treatment requests were more likely to be validated by the SMDTs if sufficient pre-therapeutic functional assessment had been performed to assess the natural history (55% vs. 32%) and if the patient had worsening rather than stable motor function (<jats:italic>p<\/jats:italic>\u2009=\u20090.029). In patients with approved treatment, a-priori criteria to define a further ineffectiveness of treatment (usually after 14\u00a0months of treatment) were proposed for 67\/72 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the context of costly treatments with few controlled studies in adults with SMA, in whom assessment of efficacy can be complex, SMDTs are \u2018real-world observatories\u2019 of great interest to establish national recommendations about indications of treatment and follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-03008-6","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:02:33Z","timestamp":1706112153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-3017","authenticated-orcid":false,"given":"Emmanuelle","family":"Salort-Campana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Magot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Noury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Behin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Masingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Deberg\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Finet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Brison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pegat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Malfatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Choumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Bellance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bedat-Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onard","family":"Feasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Vuillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Jacquin-Piques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Pereon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"3008_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(06)70940-8","volume":"7","author":"A Fleissig","year":"2006","unstructured":"Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: Are they effective in the UK? Lancet Oncol. 2006;7:935\u201343.","journal-title":"Lancet Oncol"},{"issue":"S2","key":"3008_CR2","first-page":"5","volume":"35","author":"S Attarian","year":"2019","unstructured":"Attarian S, Salort-Campana E. Renewal of Filnemus: ambitious goals for 2019\u20132023. Med Sci. 2019;35(S2):5\u20136.","journal-title":"Med Sci"},{"key":"3008_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","volume":"336","author":"J Melki","year":"1990","unstructured":"Melki J, Sheth P, Abdelhak S, Burlet P, Bachelot MF, Lathrop MG, et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12\u2013q14. The French spinal muscular atrophy investigators. Lancet. 1990;336:271\u20133.","journal-title":"Lancet"},{"key":"3008_CR4","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.","journal-title":"Sci Transl Med"},{"key":"3008_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","volume":"15","author":"F Audic","year":"2020","unstructured":"Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15:148. https:\/\/doi.org\/10.1186\/s13023-020-01414-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3008_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","volume":"15","author":"C B\u00e9rard","year":"2005","unstructured":"B\u00e9rard C, Payan C, Hodgkinson I, Fermanian J, Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15:463\u201370. https:\/\/doi.org\/10.1016\/j.nmd.2005.03.004.","journal-title":"Neuromuscul Disord"},{"key":"3008_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374. https:\/\/doi.org\/10.1002\/mus.25430.","journal-title":"Muscle Nerve"},{"key":"3008_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nmd.2021.08.010","volume":"32","author":"KJ Krosschell","year":"2022","unstructured":"Krosschell KJ, Townsend EL, Kiefer M, Simeone SD, Zumpf K, Welty L, et al. Natural history of 10-meter walk\/run test performance in spinal muscular atrophy: a longitudinal analysis. Neuromuscul Disord. 2022;32:125\u201334. https:\/\/doi.org\/10.1016\/j.nmd.2021.08.010.","journal-title":"Neuromuscul Disord"},{"key":"3008_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836\u201342. https:\/\/doi.org\/10.1002\/mus.25120.","journal-title":"Muscle Nerve"},{"key":"3008_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archpsyc.1977.01770200061005","volume":"34","author":"RM Steinbook","year":"1977","unstructured":"Steinbook RM, Jacobson AF, Mosher JC, Davies DL. The goal-attainment scale: an instructional guide for the delivery of social reinforcement. Arch Gen Psychiatry. 1977;34:923\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"3008_CR11","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","volume":"141","author":"G Bassez","year":"2018","unstructured":"Bassez G, Audureau E, Hogrel JY, Arrouasse R, Baghdoyan S, Bhugaloo H, et al. Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain. 2018;141:2855\u201365. https:\/\/doi.org\/10.1093\/brain\/awy231.","journal-title":"Brain"},{"key":"3008_CR12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/ene.15235","volume":"29","author":"S Bortolani","year":"2022","unstructured":"Bortolani S, Brusa C, Rolle E, Monforte M, De Arcangelis V, Ricci E, et al. Technology outcome measures in neuromuscular disorders: a systematic review. Eur J Neurol. 2022;29:1266\u201378. https:\/\/doi.org\/10.1111\/ene.15235.","journal-title":"Eur J Neurol"},{"key":"3008_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE. 2018;13: e0199657. https:\/\/doi.org\/10.1371\/journal.pone.0199657.","journal-title":"PLoS ONE"},{"key":"3008_CR14","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, Muscle strength and motor function in adolescents and adults with spinal muscular atrophy, et al. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neurology. 2020;95:e1988\u201398. https:\/\/doi.org\/10.1212\/WNL.0000000000010540.","journal-title":"Neurology"},{"key":"3008_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini C, De Antonio M, Taouagh N, B\u00e9hin A, Bouhour F, Echaniz-Laguna A, et al. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry. J Inherit Metab Dis. 2020;43:1219\u201331. https:\/\/doi.org\/10.1002\/jimd.12272.","journal-title":"J Inherit Metab Dis"},{"key":"3008_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365. https:\/\/doi.org\/10.3233\/JND-190416.","journal-title":"J Neuromuscul Dis"},{"key":"3008_CR17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91:1166\u201374. https:\/\/doi.org\/10.1136\/jnnp-2020-323822.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3008_CR18","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1111\/ene.14902","volume":"28","author":"T Meyer","year":"2021","unstructured":"Meyer T, Maier A, Uzelac Z, Hagenacker T, G\u00fcnther R, Schreiber-Katz O. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Eur J Neurol. 2021;28:2582\u201395. https:\/\/doi.org\/10.1111\/ene.14902.","journal-title":"Eur J Neurol"},{"key":"3008_CR19","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29:3337\u201346. https:\/\/doi.org\/10.1111\/ene.15501.","journal-title":"Eur J Neurol"},{"key":"3008_CR20","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","volume":"268","author":"B Stolte","year":"2021","unstructured":"Stolte B, Nonnemacher M, Kizina K, Bolz S, Totzeck A, Thimm A, et al. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol. 2021;268:4667\u201379. https:\/\/doi.org\/10.1007\/s00415-021-10569-8.","journal-title":"J Neurol"},{"key":"3008_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","volume":"19","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Papagiannopoulos S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics. 2022;19:464\u201375. https:\/\/doi.org\/10.1007\/s13311-022-01200-3.","journal-title":"Neurotherapeutics"},{"key":"3008_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21:42\u201352.","journal-title":"Lancet Neurol"},{"key":"3008_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16099","author":"T Kessler","year":"2023","unstructured":"Kessler T, Sam G, Wick W, Weiler M. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures. Eur J Neurol. 2023. https:\/\/doi.org\/10.1111\/ene.16099.","journal-title":"Eur J Neurol"},{"key":"3008_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NC \u00d1ungo Garz\u00f3n","year":"2023","unstructured":"\u00d1ungo Garz\u00f3n NC, Pitarch Castellano I, Sevilla T, V\u00e1zquez-Costa JF. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67:407\u201311. https:\/\/doi.org\/10.1002\/mus.27804.","journal-title":"Muscle Nerve"},{"key":"3008_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27755","volume":"67","author":"G McCluskey","year":"2023","unstructured":"McCluskey G, Lamb S, Mason S, NicFhirleinn G, Douglas I, Tirupathi S, et al. Risdiplam for the treatment of adults with spinal muscular atrophy: experience of the Northern Ireland neuromuscular service. Muscle Nerve. 2023;67:157\u201361. https:\/\/doi.org\/10.1002\/mus.27755.","journal-title":"Muscle Nerve"},{"key":"3008_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2866","author":"C Pascual-Morena","year":"2023","unstructured":"Pascual-Morena C, Mart\u00ednez-Vizca\u00edno V, Cavero-Redondo I, Mart\u00ednez-Garc\u00eda I, Moreno-Herr\u00e1iz N, \u00c1lvarez-Bueno C, et al. Efficacy of risdiplam in spinal muscular atrophy: a systematic review and meta-analysis. Pharmacotherapy. 2023. https:\/\/doi.org\/10.1002\/phar.2866.","journal-title":"Pharmacotherapy"},{"key":"3008_CR27","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/ene.15542","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022;29:3666\u201375. https:\/\/doi.org\/10.1111\/ene.15542.","journal-title":"Eur J Neurol"},{"key":"3008_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nmd.2021.12.005","volume":"32","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Zafeiridou G, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. 2022;32:185\u201394.","journal-title":"Neuromuscul Disord"},{"key":"3008_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s13760-022-02028-6","volume":"123","author":"M Gavriilaki","year":"2023","unstructured":"Gavriilaki M, Papaliagkas V, Stamperna A, Moschou M, Notas K, Papagiannopoulos S, et al. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review. Acta Neurol Belg. 2023;123:1735\u201345.","journal-title":"Acta Neurol Belg"},{"key":"3008_CR30","doi-asserted-by":"publisher","first-page":"e845","DOI":"10.1212\/WNL.0000000000011230","volume":"96","author":"B Bartels","year":"2021","unstructured":"Bartels B, de Groot JF, Habets LE, Wadman RI, Asselman FL, Nieuwenhuis EES, et al. Correlates of fatigability in patients with spinal muscular atrophy. Neurology. 2021;96:e845\u201352. https:\/\/doi.org\/10.1212\/WNL.0000000000011230.","journal-title":"Neurology"},{"key":"3008_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0269215508101742","volume":"23","author":"T-S Lynne","year":"2009","unstructured":"Lynne T-S. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil. 2009;23:362\u201370.","journal-title":"Clin Rehabil"},{"key":"3008_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27:428\u201338. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.018.","journal-title":"Neuromuscul Disord"},{"key":"3008_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, Klouvi L, Mejat A, Ouillade MC, et al. Understanding European patient expectations towardtowards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31:419\u201330. https:\/\/doi.org\/10.1016\/j.nmd.2021.01.012.","journal-title":"Neuromuscul Disord"},{"key":"3008_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neurol.2021.10.010","volume":"178","author":"C Lefeuvre","year":"2022","unstructured":"Lefeuvre C, Brisset M, Sarlon M, Petit N, Orlikowski D, Clair B, et al. Nusinersen treatment in adults with severe spinal muscular atrophy: a real-life retrospective observational cohort study. Rev Neurol. 2022;178:234\u201340. https:\/\/doi.org\/10.1016\/j.neurol.2021.10.010.","journal-title":"Rev Neurol"},{"key":"3008_CR35","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, M\u00fcschen L, Binz C, Wiehler F, et al. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol. 2020;267:2398\u2013407. https:\/\/doi.org\/10.1007\/s00415-020-09847-8.","journal-title":"J Neurol"},{"key":"3008_CR36","doi-asserted-by":"publisher","first-page":"7S40","DOI":"10.1016\/S0929-693X(20)30276-1","volume":"27","author":"C Vuillerot","year":"2020","unstructured":"Vuillerot C. State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Arch Pediatr. 2020;27:7S40\u20134. https:\/\/doi.org\/10.1016\/S0929-693X(20)30276-1.","journal-title":"Arch Pediatr"},{"key":"3008_CR37","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois JM, Bolz S, Kizina K, Totzeck A, Schlag M, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol. 2020;27:2586\u201394.","journal-title":"Eur J Neurol"},{"key":"3008_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","volume":"12","author":"CA Chiriboga","year":"2023","unstructured":"Chiriboga CA, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, et al. Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study. Neurol Ther. 2023;12:543\u201357. https:\/\/doi.org\/10.1007\/s40120-023-00444-1.","journal-title":"Neurol Ther"},{"key":"3008_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane M, Berti B, Capasso A, Coratti G, Varone A, D\u2019Amico A, et al. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine. 2023;59: 101997. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101997.","journal-title":"EClinicalMedicine"},{"key":"3008_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.36185\/2532-1900-077","volume":"41","author":"M Tosi","year":"2022","unstructured":"Tosi M, Catteruccia M, Cherchi C, Mizzoni I, D\u2019Amico A. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam. Acta Myol. 2022;41:117\u201320. https:\/\/doi.org\/10.36185\/2532-1900-077.","journal-title":"Acta Myol"},{"key":"3008_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn A, G\u00fcnther R, Ludolph A, Schwartz O, Trollmann R, Weydt P, Risdiplam Compassionate Use Program Group, et al. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2022;17:276. https:\/\/doi.org\/10.1186\/s13023-022-02420-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3008_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154969","volume":"11","author":"L Restivo","year":"2016","unstructured":"Restivo L, Apostolidis T, Bouhnik AD, Garciaz S, Aurran T, Julian-Reynier C. Patients\u2019 non-medical characteristics contribute to collective medical decision-making at multidisciplinary oncological team meetings. PLoS ONE. 2016;11: e0154969. https:\/\/doi.org\/10.1371\/journal.pone.0154969.","journal-title":"PLoS ONE"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-03008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-03008-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-03008-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:08:16Z","timestamp":1706112496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-03008-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3008"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-03008-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was classified as a service evaluation, and therefore, no formal research ethics committee approval was needed. However, the study was conducted according to research governance guidance and in compliance with the Declaration of Helsinki; that is, participants in the focus groups were given written and verbal information and time to ask questions prior to participation. They were assured of anonymity; participation was implicit of consent. All data from this study are anonymized and stripped of all sensitive personal and patient identifiers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication."}},{"value":"ESC received honoraria for advisory boards and speaking at educational events for Biogen, Argenx, UCB, Sanofi-Aventis, Roche, Lupin. GS received funding from BIOGEN FRANCE SAS to attend two medical meetings in the last 5\u00a0years. AM reports no disclosures. CT reports personal fees and non-financial support from Sanofi-Genzyme, personal fees and non-financial support from Amicus, personal fees from Akcea, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Alnylam, personal fees from Ultragenyx, personal fees from Biogen, non-financial support from Santhera, non-financial support from LFB, personal fees from Argenx, personal fees and non-financial support from UCB, outside the presented work. J-BN reports travel grants from Biogen and Roche. AB reports no disclosures. EDLC has received financial support for attending meetings and\/or travel from Biogen, Sanofi-Aventis. FB reports no disclosures. CL reports no disclosures. Masingue Marion reports no disclosures. LD reports honoraria for participation to an advisory board of Biogen. AF reports honoraria for lectures for Biogen. MB reports no disclosures. MS reports no disclosures. AP reports no disclosures. SS reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Lupin, fulcrum; support for attending meetings and\/or travel UCB Pharma, SANOFI, BIOGEN, FULCRUM THERAPEUTICS, participation on a Data Safety Monitoring Board or Advisory Board SANOFI,BIOGEN,AMICUS,UCB Pharma, ALEXION EM reports no disclosures. AC reports no disclosures. RB reports no disclosures. LF has received financial support from Biogen, Sanofi-Aventis, Roche, Lupin, LFB, Santhera, for its participation in conferences and educational events. CV reports consultancies for Roche, Novartis GT, Biogen, IPSEN and Sarepta and has been primary investigator for Roche, Novartis GT and PTCA J-P reports no disclosures. Michaud Maud reports no disclosures. YP reports consultancies, participation to advisory board and clinical trials with Avexis, Biogen, Novartis, Roche. TS reports participation to advisory boards and lectures with Roche and Biogen. PL received honoraria for advisory boards and speaking at educational events for Biogen and Roche. SA reports participation to advisory boards and lectures with Biogen and Roche. PC received honoraria for advisory boards and speaking at educational events for Biogen, Argenx, UCB, Sanofi-Aventis, Roche, Lupin, LFB, Alnylam.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}